SALT LAKE CITY, March 05, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in
the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic
treatments, announces that its subsidiary Predictive Biotech sponsored the 5th Annual Perinatal Stem Cell Society
Congress held February 28 through March 1, 2019 in Salt Lake City. Predictive Biotech uses perinatal tissue to produce human
cell and tissue products.
“We are pleased to have partnered with the Perinatal Stem Cell Society on this key conference that provides access to
leading-edge perinatal tissue research, and a networking and collaboration opportunity for researchers and industry partners,” said
Bradley C. Robinson, CEO of Predictive Technology Group. “The science utilizing perinatal tissue is progressing at an
increasingly faster pace leading to more therapeutics. Predictive supports and is a member of the Society’s working group to
bring together top clinicians and researchers to advance standards and guidelines that support the science and manufacturing of
therapeutic products derived from perinatal tissue.”
“We are pleased that Predictive has joined the perinatal society as a platinum sponsor for the second year. Through Predictive’s
market leadership position and commitment to advancing the science, quality and therapeutic use of perinatal tissue, we all move
another step closer in delivering on the promise of these tissues,” said Kyle Cetrulo President and Founder of the Perinatal Stem
Cell Society. “Attendees benefit from this open forum in a collaborative environment to discuss industry and science topics that
are affecting one of the most significant medical advances of our time.”
Perinatal Stem Cell Society
The Perinatal Stem Cell Society, Inc. is a non-profit organization founded in 2013 on the basic principle that stem cells from
perinatal tissues contain enormous, untapped potential to treat many diseases and disorders. Perinatal stem cell sources
include amnion, amniotic fluid, cord blood, cord tissue/Wharton’s jelly, as well as placental blood and placental tissue. Perinatal
stem cells are formed around the time of birth and are classified as adult stem cells. Yet because they are more primitive
than stem cells found in bone marrow, adipose tissue or other traditional sources of adult stem cells, they have greater
therapeutic potential.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and
companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, Predictive Diagnostics and Predictive
Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue
products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that
assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.
Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially
forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and
demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new
product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional
intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may
identify from time to time in the future.
Contact:
Investors
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
